CompoAtlas

Femivia Bien-être menstruel

Food supplement declared in France, decision dated 11 November 2026

Femivia Bien-être menstruel (PhytoResearch) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: tryptophane 200 mg per day, Alchemilla vulgaris 100 mg per day, Zingiber officinale 100 mg per day, Valeriana officinalis 60 mg per day, Matricaria chamomilla 37.5 mg per day. 2 rules of use apply to its ingredients (limits and warnings).

Brand
PhytoResearch
Food business operator placing the product on the market
PHYTORESEARCH
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 gélule par jour
Directions for use
Prendre une gélule de la formule 1 pendant 14 jours à partir du premier jour des règles. Poursuivre avec une gélule de la formule 2 jusqu'à la fin de son cycle.
Intended populations
Men and women aged 18 and over, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, History of breast cancer, Pregnant women, Taking medication
Objectives stated by the manufacturer (these are not authorised claims)
Menstrual cycles

Declaration 382045, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Alchemilla vulgaris L.Parties aériennesPoudre (de plantes séchées ou broyées)100 mg
Zingiber officinale RoscoeRhizomeExtrait sec hydroalcoolique100 mg
Valeriana officinalis L.RacineExtrait sec hydroalcoolique60 mg
Matricaria chamomilla L.FleurExtrait sec hydroalcoolique37.5 mg
Crocus sativus L.StigmatesExtrait sec hydroalcoolique30 mg
Vitex agnus-castus L.FruitPoudre (de plantes séchées ou broyées)30 mg

Substances

NamePer day
tryptophane200 mg

Other active ingredients

NamePer day
Fibres solubles d'acacianot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg

Other ingredients

Farine de noix de coco, Gélule végétale

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé en cas d’allergie croisée connue, notamment à la famille des Astéracées. Déconseillé aux personnes sous antidépresseurs. Déconseillé en cas de cancer hormonodépendant (ou d’antécédents personnels ou familiaux de tels cancers), de tumeurs hypophysaires à prolactine ou d’antécédents de troubles hypophysaires. En cas de traitement médical, demander conseil à un professionnel de santé.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Zingiber officinale Roscoe
    Read the warning, when it applies and the studies cited

    GINGER - ZINGIBER OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 19 December 2025

  • Valeriana officinalis L.
    Read the warning, when it applies and the studies cited

    Valerian - VALERIANA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).

    Sources cited by Health Canada (3)
    • Barnes J, Anderson LA, Phillipson JD. Herbal Medicines: A guide for healthcare professionals. 2nd ed. London (UK): Pharmaceutical Press; 2002.
    • Blumenthal M, Hall T, Goldberg A, Kunz T, Dinda K, Brinckmann J, Wollschlaeger B, editors. 2003. The ABC Clinical Guide to Herbs: Valerian. Austin, Texas: American Botanical Council.
    • Mills E, Dugoua J, Perri D, Koren G. 2006. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (GB): Taylor and Francis Medical.

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).

    Sources cited by Health Canada (2)
    • Gennaro AR, Marderosian AHD, Hanson GR, Medwick T, editors. 2000. Remington: The Science and Practice of Pharmacy, 20th edition. Philadelphia (PA): Lippincott Williams & Wilkins.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications. 2010.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 1992. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2002. Pharmacotherapy: A Pathophysiologic Approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.
    • EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 July 2024

  • Matricaria chamomilla L.
    Read the warning, when it applies and the studies cited

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).

    Cautions and warnings

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Health Canada monograph dated 19 December 2025

    German Chamomile - Matricaria Chamomilla Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 31 January 2025

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal

    Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 29 May 2026

  • Vitex agnus-castus L.
    Read the warning, when it applies and the studies cited

    CHASTE TREE - VITEX AGNUS-CASTUS

    Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).

    Sources cited by Health Canada (4)
    • Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Contraindications

    Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).

    Sources cited by Health Canada (9)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
    • Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Health Canada monograph dated 28 March 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : PhytoResearch

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Femivia Bien-être menstruel (PhytoResearch): composition and regulation”, https://compoatlas.com/en/supplements/products/382045-femivia-bien-etre-menstruel, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line